NUWE.NASDAQNuwellis, INC

DEF: Nuwellis Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

Sentiment:

Proxy Statement


Nuwellis, Inc. is asking stockholders to approve a reverse stock split to comply with Nasdaq's continued listing requirements at the annual meeting on May 20, 2025.

Summary

  • Nuwellis, Inc. is holding its 2025 annual meeting of stockholders virtually on May 20, 2025.
  • The meeting will address the election of two Class III directors, a proposal to approve a reverse stock split, ratification of the appointment of Baker Tilly US, LLP as the independent registered public accounting firm, and authorization for adjournment of the meeting to solicit additional proxies for the reverse stock split proposal.
  • The proposed reverse stock split would combine outstanding common stock at a ratio ranging from 1-for-5 to 1-for-70, determined at the discretion of the Board of Directors.
  • This action is intended to enable the company to comply with Nasdaq's continued listing requirements.
  • As of March 25, 2025, Nuwellis had 4,373,968 shares of common stock outstanding.
  • The Board of Directors unanimously recommends voting for each director nominee and for Proposals 2, 3, and 4.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily conveying information about the upcoming annual meeting and proposals. The need for a reverse stock split introduces a slightly negative element, but the overall sentiment is balanced.

Positives

  • The Board is taking proactive steps to maintain the company's Nasdaq listing.
  • The virtual meeting format provides greater access for stockholders.
  • The Board is recommending stockholders vote for all proposals.

Negatives

  • The company needs to implement a reverse stock split to maintain its Nasdaq listing, which may be perceived negatively by investors.
  • The reverse stock split could lead to increased volatility and decreased liquidity of the common stock.
  • Delisting from Nasdaq could impair the company's ability to raise additional funds.

Risks

  • Failure to maintain compliance with Nasdaq listing requirements could result in delisting.
  • The reverse stock split may not be effective in maintaining the minimum bid price.
  • Delisting from Nasdaq could negatively impact the market price and liquidity of the company's common stock.
  • The company is subject to a Mandatory Panel Monitor for a period of one year from December 17, 2024, and could be delisted if it falls out of compliance with the Stockholders Equity Requirement.

Future Outlook

The company intends to actively monitor its performance with respect to the Nasdaq listing standards and will consider available options to resolve any deficiency and maintain compliance with the Nasdaq rules. The Board may implement the reverse stock split if it believes necessary to maintain the Companys listing on Nasdaq and to ensure that a sufficient number of shares of our common stock are authorized to satisfy the Companys obligations.

Management Comments

  • The Board believes that maintaining the listing of the Company's common stock on Nasdaq is in the best interests of the Company and its stockholders.

Industry Context

Many microcap companies face challenges in maintaining Nasdaq listing compliance, particularly regarding minimum bid price and stockholders' equity requirements. Reverse stock splits are a common tool used by these companies to regain compliance, although they can have negative consequences for investors.

Comparison to Industry Standards

  • Comparable companies that have recently undertaken reverse stock splits to maintain Nasdaq listing include: TherapeuticsMD, Inc. (TXMD) which implemented a 1-for-50 reverse stock split in 2020; Citius Pharmaceuticals, Inc. (CTXR) which implemented a 1-for-10 reverse stock split in 2023; and Evoke Pharma, Inc. (EVOK) which implemented a 1-for-10 reverse stock split in 2020.
  • These companies, like Nuwellis, faced challenges in maintaining the minimum bid price and sought to increase their share price to remain compliant with Nasdaq listing requirements.
  • The success of a reverse stock split in maintaining listing and improving investor sentiment varies, and depends on the company's underlying financial performance and market conditions.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
President and Chief Executive OfficerNestor Jaramillo, Jr.John L. Erb (Interim)February 23, 2025Retirement of Nestor Jaramillo, Jr.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Insider Trading PolicyAmended and Restated Insider Trading Compliance Policy adopted, effective April 1, 2025, to prevent insider trading and promote compliance with insider trading laws.April 1, 2025Aims to strengthen internal controls and prevent improper conduct related to trading in company securities.

Stakeholder Impact

  • Stockholders may experience a change in the number of shares they own due to the reverse stock split.
  • The reverse stock split could impact the market price and liquidity of the company's common stock.
  • Employees may be affected by changes in the company's financial stability and future prospects.

Next Steps

  • Stockholders will vote on the proposals at the annual meeting on May 20, 2025.
  • If approved, the Board will determine the specific ratio for the reverse stock split and its timing within twelve months.
  • The company will file the Reverse Stock Split Certificate of Amendment with the Secretary of State of the State of Delaware if the Board decides to implement the reverse stock split.

Key Dates

DateDescription
September 20, 2011Date on which the Fourth Amended and Restated Certificate of Incorporation of the Corporation was originally filed with the Secretary of State of the State of Delaware
December 7, 2023Nuwellis received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement.
June 4, 2024Initial deadline for Nuwellis to regain compliance with the Minimum Bid Price Requirement.
May 23, 2024Nuwellis received a letter from Nasdaq regarding non-compliance with the minimum stockholders equity requirement.
June 5, 2024Nuwellis received a letter from Nasdaq indicating continued non-compliance with Nasdaq Marketplace Rule 5550(a)(2).
June 27, 2024Nuwellis effected a 1-for-35 reverse stock split of its outstanding Common Stock.
July 18, 2024Nuwellis received a letter from the Staff informing the Company that it had regained compliance with the Minimum Bid Price Requirement.
July 23, 2024The Company addressed the Panel and presented its plan of compliance for the Stockholders Equity Requirement to the Panel.
August 8, 2024Nuwellis was notified by Nasdaq that the Panel had granted the Companys request for continued listing, subject to, among other things, the Companys filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, evidencing compliance with the Stockholders Equity Requirement.
September 30, 2024Quarter end date for which Nuwellis needed to evidence compliance with the Stockholders Equity Requirement.
November 12, 2024Nuwellis filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 evidencing compliance with the Stockholders Equity Requirement.
December 17, 2024Nuwellis received a letter from the Staff indicating that the Company regained compliance with the Stockholders Equity Requirement.
March 25, 2025Record date for the 2025 annual meeting of stockholders.
April 14, 2025Date of proxy statement.
May 17, 2025Deadline to register for the virtual annual meeting.
May 20, 2025Date of the 2025 annual meeting of stockholders.
December 15, 2025Deadline for stockholders to submit proposals for inclusion in the 2026 proxy statement.
January 20, 2026Earliest date for stockholders to submit director nominations or other business proposals for the 2026 annual meeting (outside of Rule 14a-8).
February 19, 2026Latest date for stockholders to submit director nominations or other business proposals for the 2026 annual meeting (outside of Rule 14a-8).
May 20, 2026First anniversary of the 2025 annual meeting.

Keywords

reverse stock split, Nasdaq, annual meeting, proxy statement, directors, Baker Tilly, listing requirements, common stock, Nuwellis

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.